Baseline characteristics of patients in prednisone and pyridostigmine treatment groups
| Characteristics | Prednisone group (n = 55) | Pyridostigmine group (n = 34) | p Value* |
|---|---|---|---|
| Abnormal acetylcholine receptor antibody | (n = 26) Mean (SD) | (n = 15) Mean (SD) | |
| PCT, prism cover test. | |||
| *From Wilcoxon rank sum test. | |||
| †From exact χ2 test. | |||
| Age (years) | 48.4 (15.5) | 52.6 (23.8) | 0.16 |
| Acetylcholine receptor antibody (nmol/l) | 2.7 (9.6) | 2.8 (6.4) | 0.35 |
| Primary gaze, horizontal PCT (dioptres) | 12.2 (12.1) | 13.3 (10.8) | 0.54 |
| Primary gaze, vertical PCT (dioptres) | 5.5 (6.3) | 5.4 (6.4) | 0.84 |
| Downward gaze, horizontal PCT (dioptres) | 9.8 (10.4) | 11.1 (9.5) | 0.44 |
| Downward gaze, vertical PCT (dioptres) | 6.3 (6.2) | 5.5 (6.9) | 0.50 |
| n (%) | n (%) | p Value† | |
| Sex—male | 30 (54.6%) | 17 (50.0%) | 0.83 |
| Abnormal acetylcholine receptor antibody | 26 (47.2%) | 17 (50%) | 0.71 |
| Diplopia primary gaze | 52 (94.6%) | 29 (85.3%) | 0.25 |
| Diplopia downward gaze | 45 (81.8%) | 27 (79.4%) | 0.79 |
| Ptosis, unilateral | 25 (45.5%) | 17 (50.0%) | 0.83 |
| Ptosis, bilateral | 6 (10.9%) | 11 (32.4%) | 0.02 |